Neurocrine Biosciences, Inc. $NBIX Stock Holdings Raised by AlphaQuest LLC

AlphaQuest LLC lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3,271.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,149 shares of the company’s stock after purchasing an additional 12,759 shares during the period. AlphaQuest LLC’s holdings in Neurocrine Biosciences were worth $1,846,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of NBIX. Arizona State Retirement System increased its holdings in Neurocrine Biosciences by 1.1% in the third quarter. Arizona State Retirement System now owns 29,207 shares of the company’s stock valued at $4,100,000 after buying an additional 321 shares during the last quarter. SYM FINANCIAL Corp acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter worth approximately $247,000. Summit Global Investments grew its position in shares of Neurocrine Biosciences by 214.0% in the 3rd quarter. Summit Global Investments now owns 36,155 shares of the company’s stock worth $5,075,000 after acquiring an additional 24,639 shares in the last quarter. Golden State Wealth Management LLC increased its holdings in shares of Neurocrine Biosciences by 120.5% in the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after acquiring an additional 100 shares during the last quarter. Finally, Great Lakes Advisors LLC raised its position in shares of Neurocrine Biosciences by 2.4% during the 3rd quarter. Great Lakes Advisors LLC now owns 3,605 shares of the company’s stock valued at $506,000 after acquiring an additional 84 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Down 1.4%

NASDAQ NBIX opened at $136.06 on Friday. The company has a 50-day moving average price of $143.13 and a two-hundred day moving average price of $140.19. Neurocrine Biosciences, Inc. has a 52 week low of $84.23 and a 52 week high of $160.18. The stock has a market cap of $13.57 billion, a price-to-earnings ratio of 32.55, a price-to-earnings-growth ratio of 0.73 and a beta of 0.28.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.59. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The company had revenue of $794.90 million for the quarter, compared to analysts’ expectations of $746.61 million. During the same quarter in the previous year, the company posted $1.81 earnings per share. The business’s revenue for the quarter was up 27.8% compared to the same quarter last year. As a group, equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on NBIX shares. Stifel Nicolaus lifted their price objective on shares of Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Canaccord Genuity Group lifted their price target on shares of Neurocrine Biosciences from $160.00 to $164.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Royal Bank Of Canada boosted their price objective on shares of Neurocrine Biosciences from $160.00 to $180.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Morgan Stanley reissued an “equal weight” rating and issued a $175.00 target price (up previously from $173.00) on shares of Neurocrine Biosciences in a report on Thursday, January 8th. Finally, Zacks Research lowered Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $174.25.

Insider Activity

In related news, Director George J. Morrow sold 15,000 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $143.37, for a total transaction of $2,150,550.00. Following the sale, the director directly owned 7,068 shares in the company, valued at $1,013,339.16. The trade was a 67.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Darin Lippoldt sold 4,376 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $159.65, for a total transaction of $698,628.40. Following the completion of the sale, the insider directly owned 43,405 shares of the company’s stock, valued at $6,929,608.25. The trade was a 9.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 80,266 shares of company stock worth $11,400,517 over the last ninety days. 4.80% of the stock is currently owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.